Literature DB >> 10415806

CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer.

M G Selzer1, B Zhu, N L Block, B L Lokeshwar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10415806     DOI： 10.1111/j.1749-6632.1999.tb07760.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  11 in total

1.  Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Authors:  Jing Li; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Authors:  Bal L Lokeshwar
Journal:  Pharmacol Res       Date:  2010-11-18       Impact factor: 7.658

4.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

6.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.

Authors:  Muzharul M Islam; Christopher D Franco; David W Courtman; Michelle P Bendeck
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

7.  Antenna effect and phosphorescence spectra to find the location of drug tetracycline in bovine β-lactoglobulin A.

Authors:  Moumita Mukherjee; Pinki Saha Sardar; Pritam Roy; Swagata Dasgupta; Maitrayee Basu Roy; Sanjib Ghosh
Journal:  J Biol Inorg Chem       Date:  2018-07-13       Impact factor: 3.358

8.  A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.

Authors:  Quincy S C Chu; Bahram Forouzesh; Samira Syed; Monica Mita; Garry Schwartz; Joshua Cooper; Joshua Copper; Janet Curtright; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2007-01-20       Impact factor: 3.651

9.  Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells.

Authors:  Hairong Song; Mona Fares; Kim R Maguire; Ake Sidén; Zuzana Potácová
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

10.  Minocycline treatment increases resistance to oxidative stress and extends lifespan in Drosophila via FOXO.

Authors:  Gang Jun Lee; Jin Ju Lim; Seogang Hyun
Journal:  Oncotarget       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.